TaqPath COVID-19 Multiplex Diagnostic Solution
In response to the novel coronavirus (SARS-CoV-2) outbreak, Thermo Fisher Scientific has worked rapidly to develop a multiplex real-time PCR diagnostic kit to enable clinical and public health laboratories to quickly diagnose COVID-19 caused by SARS-CoV-2 infection.
- Built-in redundancy (3 targets) compensates for emerging SARS-CoV-2 mutations and variants, helping provide confidence in your results
- Targets areas unique to SARS-CoV-2* virus to reduce detection of other coronaviruses
*GISAID and GenBank databases as of May 7, 2021
This test uses a multi-target design that includes an S-gene target. If a sample with the 69-70del S-gene mutation is tested using the TaqPath COVID-19 Combo Kit, it will result in an S-gene dropout. The European CDC and U.S. FDA have noted this pattern of detection may help with early identification of the Alpha variant (B.1.1.7)
Concerned about the impact of new variants on your COVID-19 test performance? There is peace of mind with the TaqPath COVID-19 2.0 Assays.
Prepare yourself for flu season with the TaqPath COVID-19, Flu A, Flu B Combo Kit, a single test to detect and differentiate between SARS-CoV-2, influenza A, and influenza B.
Authorized on some of the most-used real-time PCR instruments in the world
- Applied Biosystems 7500 Fast Dx Real-Time PCR instrument
- Applied Biosystems 7500 Fast Real-Time PCR Instrument
- Applied Biosystems 7500 Real-Time PCR Instrument
- QuantStudio 5 Real-Time PCR Instrument, 96-well, 0.2 mL block
- QuantStudio 5 Real-Time PCR Instrument, 96-well, 0.1 mL block
- QuantStudio 5 Dx Real-Time PCR Instrument, 384-well block
- QuantStudio 7 Flex Real-Time PCR Instrument, 384–well block
Authorized for use with seven specimen types, requiring only 200 to 400 μL of sample
- Bronchoalveolar lavage (BAL)
- Mid-turbinate swabs
- Nasal swabs
- Nasopharyngeal swabs
- Nasopharyngeal aspirate (nasal aspirate)
- Oropharyngeal swabs
- Saliva collected with the Spectrum Solutions SpectrumDNA SDN